MaxCyte (MXCT) Competitors $2.22 -0.06 (-2.63%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.22 0.00 (-0.05%) As of 07/11/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MXCT vs. IBTA, NEO, WLDN, NXTT, IIIV, PRSU, NRDS, RSKD, TSSI, and PSFEShould you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include Ibotta (IBTA), NeoGenomics (NEO), Willdan Group (WLDN), Next Technology (NXTT), i3 Verticals (IIIV), Pursuit Attractions and Hospitality (PRSU), NerdWallet (NRDS), Riskified (RSKD), TSS (TSSI), and Paysafe (PSFE). These companies are all part of the "business services" industry. MaxCyte vs. Its Competitors Ibotta NeoGenomics Willdan Group Next Technology i3 Verticals Pursuit Attractions and Hospitality NerdWallet Riskified TSS Paysafe MaxCyte (NASDAQ:MXCT) and Ibotta (NYSE:IBTA) are both small-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk. Which has preferable valuation and earnings, MXCT or IBTA? Ibotta has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Ibotta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxCyte$38.63M6.12-$41.06M-$0.40-5.55Ibotta$367.25M2.57$68.74M$1.4825.16 Which has more risk & volatility, MXCT or IBTA? MaxCyte has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Ibotta has a beta of -1.29, suggesting that its stock price is 229% less volatile than the S&P 500. Do analysts prefer MXCT or IBTA? MaxCyte presently has a consensus price target of $7.50, indicating a potential upside of 237.84%. Ibotta has a consensus price target of $61.60, indicating a potential upside of 65.41%. Given MaxCyte's stronger consensus rating and higher probable upside, research analysts clearly believe MaxCyte is more favorable than Ibotta.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MaxCyte 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ibotta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do institutionals & insiders believe in MXCT or IBTA? 68.8% of MaxCyte shares are owned by institutional investors. 3.3% of MaxCyte shares are owned by insiders. Comparatively, 16.1% of Ibotta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is MXCT or IBTA more profitable? Ibotta has a net margin of 16.24% compared to MaxCyte's net margin of -110.92%. Ibotta's return on equity of 15.04% beat MaxCyte's return on equity.Company Net Margins Return on Equity Return on Assets MaxCyte-110.92% -19.90% -17.24% Ibotta 16.24%15.04%9.71% Does the media prefer MXCT or IBTA? In the previous week, MaxCyte had 2 more articles in the media than Ibotta. MarketBeat recorded 5 mentions for MaxCyte and 3 mentions for Ibotta. MaxCyte's average media sentiment score of 0.78 beat Ibotta's score of 0.26 indicating that MaxCyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ibotta 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryIbotta beats MaxCyte on 9 of the 16 factors compared between the two stocks. Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MXCT vs. The Competition Export to ExcelMetricMaxCyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$236.24M$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.07%4.01%P/E Ratio-5.5520.7128.2120.26Price / Sales6.12292.31432.3899.78Price / CashN/A42.1137.1257.67Price / Book1.147.638.045.49Net Income-$41.06M-$55.05M$3.19B$250.45M7 Day Performance-0.67%8.43%3.63%4.79%1 Month Performance-2.20%5.42%4.06%7.68%1 Year Performance-50.56%2.03%30.02%16.44% MaxCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MXCTMaxCyte2.9172 of 5 stars$2.22-2.6%$7.50+237.8%-50.2%$236.24M$38.63M-5.5580News CoverageIBTAIbotta3.1304 of 5 stars$36.63-0.9%$61.60+68.2%N/A$935.47M$367.25M24.75N/AGap DownNEONeoGenomics3.4948 of 5 stars$7.31+1.8%$13.83+89.2%-49.4%$924.03M$660.57M-11.982,200WLDNWilldan Group4.0707 of 5 stars$62.51+0.3%$51.50-17.6%+130.9%$903.15M$565.80M36.991,761News CoverageAnalyst ForecastNXTTNext Technology1.2051 of 5 stars$2.30+12.7%N/A-48.2%$889.98M$1.80M0.008Positive NewsIIIVi3 Verticals3.5982 of 5 stars$27.48+4.0%$29.57+7.6%+26.8%$878.09M$229.92M6.251,480News CoveragePositive NewsPRSUPursuit Attractions and Hospitality0.9689 of 5 stars$28.80-0.4%$29.67+3.0%N/A$817.16M$366.49M2.341,500Positive NewsNRDSNerdWallet3.5055 of 5 stars$10.97+0.4%$15.00+36.7%-27.7%$814.42M$687.60M28.13770News CoverageRSKDRiskified1.4993 of 5 stars$5.00+0.6%$6.03+20.6%-19.7%$801.21M$327.52M-22.73780Positive NewsTSSITSSN/A$28.83-4.7%N/A+587.9%$756.87M$148M80.0970News CoverageGap DownPSFEPaysafe3.3859 of 5 stars$12.65+0.6%$16.95+34.0%-29.7%$752.80M$1.70B-632.503,300News Coverage Related Companies and Tools Related Companies Ibotta Alternatives NeoGenomics Alternatives Willdan Group Alternatives Next Technology Alternatives i3 Verticals Alternatives Pursuit Attractions and Hospitality Alternatives NerdWallet Alternatives Riskified Alternatives TSS Alternatives Paysafe Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MXCT) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
